- Home
- RCUS vs BST Comparison
RCUS vs BST Comparison
Compare RCUS & BST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- BST
- Stock Information
- Founded
- RCUS 2015
- BST 2014
- Country
- RCUS United States
- BST United States
- Employees
- RCUS N/A
- BST N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- BST Finance Companies
- Sector
- RCUS Health Care
- BST Finance
- Exchange
- RCUS Nasdaq
- BST Nasdaq
- Market Cap
- RCUS 1.2B
- BST 1.4B
- IPO Year
- RCUS 2018
- BST N/A
- Fundamental
- Price
- RCUS $12.20
- BST $39.63
- Analyst Decision
- RCUS Buy
- BST
- Analyst Count
- RCUS 8
- BST 0
- Target Price
- RCUS $20.71
- BST N/A
- AVG Volume (30 Days)
- RCUS 772.4K
- BST 90.0K
- Earning Date
- RCUS 11-05-2025
- BST 01-01-0001
- Dividend Yield
- RCUS N/A
- BST 7.58%
- EPS Growth
- RCUS N/A
- BST N/A
- EPS
- RCUS N/A
- BST N/A
- Revenue
- RCUS $262,000,000.00
- BST N/A
- Revenue This Year
- RCUS N/A
- BST N/A
- Revenue Next Year
- RCUS N/A
- BST N/A
- P/E Ratio
- RCUS N/A
- BST N/A
- Revenue Growth
- RCUS 6.07
- BST N/A
- 52 Week Low
- RCUS $6.50
- BST $27.87
- 52 Week High
- RCUS $18.98
- BST $40.21
- Technical
- Relative Strength Index (RSI)
- RCUS 75.43
- BST 56.20
- Support Level
- RCUS $10.40
- BST $38.16
- Resistance Level
- RCUS $11.84
- BST $40.07
- Average True Range (ATR)
- RCUS 0.54
- BST 0.46
- MACD
- RCUS 0.16
- BST -0.01
- Stochastic Oscillator
- RCUS 98.35
- BST 76.70
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About BST BlackRock Science and Technology Trust of Beneficial Interest
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objective is to provide income and total return through a combination of current income, current gains, and long-term capital appreciation. It focuses on investing, under a normal market condition in equity securities of science and technology companies.